Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Second Attempt

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

Executive Summary

With the positive results of the ADVANCE II study of Bristol-Myers Squibb/Pfizer's apixaban now offsetting the failed non-inferiority of the earlier ADVANCE I study, the ADVANCE III study is shaping up to be the tie-breaker for how the investigational anticoagulant stacks up against Sanofi-Aventis' low molecular weight heparin Lovenox (enoxaparin) in patients undergoing orthopedic surgery

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

See All
UsernamePublicRestriction

Register

PS004396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By